FT Options’s Akebia Therapeutics AKBA Stock Holding History

FT Options’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$104K	Buy	+30,000	New	+$461K	0.16%	96
2017 Q2	–	Sell	-5,000	Closed	-$5K	–	196
2017 Q1	$5K	Buy	+5,000	New	+$48.8K	0.01%	245
2016 Q3	–	Sell	-45,000	Closed	-$16K	–	368
2016 Q2	$16K	Sell	45,000 -156,800	-78%	-$1.37M	0.01%	263
2016 Q1	$10K	Buy	+201,800	New	+$1.64M	0.01%	240

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FT Options's AKBA Position: Q3 2017 in Review

FT Options sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 30 shares — an estimated $461 sold.

FT Options first reported a position in AKBA in Q4 2015 and held it in 7 quarters. The position peaked at $3.52M in Q4 2016. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

FT Options reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
FT Options sold 30 Akebia Therapeutics shares in Q3 2017, an estimated $461.
FT Options first reported a position in Akebia Therapeutics in Q4 2015 and held it in 7 quarters.
FT Options's Akebia Therapeutics position peaked at $3.52M in Q4 2016.
119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.